Bio-Techne Corporation TECH

Full chart Compare
Set alert

Price alert · TECH

All alert types
72.66 USD -0.01 (-0.01%)

At closeNov 3, 2026, 7:04 PM EST

72.52 -0.14 -0.19%

After hours · Nov 3, 7:04 PM ET

72.63 Day range 72.72
43.20 52-week range 72.75
YTD
+23.55%
1 year
+18.61%
Market cap
11.41B
Revenue (ttm)
1.22B
Profit margin
14.97%
EPS (ttm)
1.16
Shares out
157.06M
P/E ratio
62.64
Forward P/E
31.44
Dividend
0.32 (0.44%)
Ex-dividend date
Aug 23, 2026
YTD return
+23.55%
1-year return
+18.61%
Volume
3.51M
Avg volume
2.80M
Open
72.72
Previous close
72.67
Day's range
72.63 – 72.72
52-week range
43.20 – 72.75
Beta
1.27
Analysts
Hold
Price target
70.50 (-3.0%)
Earnings date
Nov 4, 2026

5D +0.01 (+0.01%)

72.6572.70WedThuFriMonTue72.65

Key statistics

Enterprise value
11.42B
PEG ratio
2.17
Price / sales
9.39
Price / book
5.38
Dividend yield
0.44%
Payout ratio
27.59%
Revenue growth
1.30%
Free cash flow
229.65M
Total cash
265.48M
Total debt
289.09M
Return on equity
9.03%
Short % of float
4.82%
50-day average
72.46
200-day average
63.17

Financials — quick view

All financials
TECH Revenue — quarterly 321.19M
2023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 2026
TECH Net income — quarterly 54.62M
2023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 2026
TECH EPS — quarterly 0.35
2023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 2026

Earnings

TECH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20260.44———
Aug 12, 2026Jun 30, 20260.5190.520.00+0.19%
May 6, 2026Mar 31, 20260.550.53-0.02-3.64%
Feb 4, 2026Dec 31, 20250.430.46+0.03+6.98%
Nov 5, 2025Sep 30, 20250.42140.420.00-0.33%
Aug 6, 2025Jun 30, 20250.500.53+0.03+6.00%

Upgrades / downgrades

TECH analyst upgrades and downgrades
DateFirmActionFromTo
Aug 13, 2026Wells FargodownOverweightEqual-Weight
Jul 9, 2026RBC CapitaldownOutperformSector Perform
Jun 30, 2026TD CowendownBuyHold
Jun 30, 2026BenchmarkdownBuyHold
Jun 29, 2026CitigroupdownBuyNeutral
Jun 26, 2026Stephens & Co.downOverweightEqual-Weight

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TECH — it syncs with the Stock Master app.

Insider holders

TECH insider holders
InsiderRelationLatest transactionDateShares held
BAUMGARTNER ROBERT VDirectorStock Award(Grant)Oct 28, 202659,634
BUSHMAN JULIE L.DirectorStock Award(Grant)Oct 28, 202611,525
GEIST WILLIAMOfficerConversion of Exercise of derivative securityAug 13, 202624,943
HIGGINS JOHN LDirectorStock Award(Grant)Oct 28, 202680,004
HIPPEL JAMESChief Financial OfficerConversion of Exercise of derivative securityAug 13, 2026170,183
KEEGAN JOSEPH DDirectorStock Award(Grant)Oct 28, 202618,161

Institution ownership

TECH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.93%14,025,8161.02BJun 29, 2026
FMR, LLC8.15%12,794,784929.67MJun 29, 2026
Vanguard Capital Management LLC6.51%10,218,558742.48MJun 29, 2026
Goldman Sachs Group Inc4.68%7,343,324533.57MJun 29, 2026
HBK Investments L P4.35%6,825,000495.90MJun 29, 2026
Vanguard Portfolio Management LLC4.14%6,506,360472.75MJun 29, 2026

Fund ownership

TECH fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%4,968,867361.04MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.58%4,056,808294.77MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.28%3,586,562260.60MJun 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF1.72%2,707,457196.72MSep 29, 2026
Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund1.66%2,604,519189.24MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%2,089,474151.82MSep 29, 2026